Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 341

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 341
---
 the effectiveness of the Registration Statement registering the shares of F-99

TuHURA common stock issuable to the Kineta stockholders in the Mergers, and other customary closing conditions. The Mergers are currently targeted to close in the second quarter of 2025. Note 2-Summaryof significant accounting policies Basis for Consolidation- The condensed consolidated financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero Biopharmaceuticals Holdings Inc., Adgero Biopharmaceuticals, Inc., Veterinary Oncology Services, and Legacy TuHURA. All intercompany balances and transactions have been eliminated in consolidation. The Company’s significant accounting policies are described herein and in Note 2, “Summary of significant accounting policies,” in the 2024 Annual Report. There have been no changes to the significant accounting policies during the three months ended March 31, 2025 Accounting Estimates- The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect various amounts reported in condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Grant Income- The Company assumed in the Kintara Merger a $ 2,000,000Business Innovation Research grant, a two year grant that was initiated in June 2023 and set to expire in June 2025, to support the clinical development of REM-001for the treatment of CMBC. As of the closing date of the Kintara Merger, the balance under the grant was $ 900,000. For the three months ended March 31, 2025 and 2024, the Company recognized approximately $ 252,000and $ 0of grant income in the condensed consolidated statements of operations. Research and Development Expenses- Research and development consists of expenses incurred in connection with the discovery and development of product candidates. The Company expenses research and development costs as incurred. Concentration of Credit Risk- The Company maintains cash balances in domestic financial institutions. These balances are insured by the Federal Deposit Insurance Corporation up to $ 250,000. As of March 31, 2025, the uninsured portion of cash held by the Company was approximately $ 5,600,000.